NeuroPace Inc (NPCE) company profile
Close on Nov 13, 2026Market cap $259.49MP/E –Yield 0.00%
About NeuroPace
Surgical & Medical Instruments & Apparatus, SIC 3841
The company develops and commercializes medical devices designed to treat epilepsy by reducing or eliminating seizures. Its primary product is the RNS System, a brain-responsive neuromodulation system that continuously monitors intracranial brain activity, identifies individualized abnormal patterns, and delivers targeted electrical pulses to the seizure origin. In addition to the implantable neurostimulator and lead components, the platform includes clinician and patient management tools such as the Patient Remote Monitor, the Physician Tablet, the Patient Data Management System, and the nSight Platform. Its customer base consists of epileptologists, functional neurosurgeons, and comprehensive epilepsy centers treating adult patients with drug-resistant focal epilepsy.
The company's commercial operations are concentrated primarily in the United States across more than 230 Level 4 comprehensive epilepsy centers as well as outpatient community settings. Its commercial reach also includes distribution in Israel and case-by-case availability through a special access program in Canada. Over 8,000 patients have received the RNS System.
Summary of the business section of NeuroPace's latest annual report, written by StockData.
Company profile
Company
- Legal name
- NeuroPace Inc
- Headquarters
- Mountain View, CA
- Address
- 455 N. Bernardo Avenue 94043
- Phone
- (650) 237-2700
- Website
- www.neuropace.com
- Employees
- 209, Dec 31, 2025
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers, San Jose, California
Stock & identifiers
- Ticker
- NPCE
- Exchange
- Nasdaq
- IPO date
- Apr 23, 2021
- Shares outstanding
- 34M, Aug 7, 2026
- Public float
- $306.20M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- SEC CIK
- 1528287
- CUSIP
- 641288105
- ISIN
- US6412881053
- FIGI
- BBG001KWZD52
- Share class FIGI
- BBG001V0SVB1
- EIN
- 22-3550230
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Joel Becker | CHIEF EXECUTIVE OFFICER, Director | 138,000 |
| Martha Morrell | CHIEF MEDICAL OFFICER | 51,357 |
| Patrick F. Williams | Chief Financial Officer | 67,508 |
| Rebecca Kuhn | CHIEF FINANCIAL OFFICER | 131,613 |
| Uri Geiger | Director | 4,451,485 |
| Rakhi Kumar | Director | 23,039 |
| Frank M. Fischer | Director | 599,534 |
| R. Scott Huennekens | Director | 2,890 |
| Renee Ryan | Director | 2,890 |
| Lisa Andrade | Director | 2,890 |
| Joseph Lacob | Director | 238,308 |
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Joel Becker President and Chief Executive Officer | $567.57K | $587.34K | $701.85K | $551.81K | – | $2.41M | -20% |
| Patrick Williams Chief Financial Officer | $263.46K | $539.76K | $650.45K | $192.26K | – | $1.65M | – |
| Martha Morrell Chief Medical Officer | $489.84K | $140.63K | $168.18K | $235.47K | – | $1.03M | -12% |
| Rebecca Kuhn Former Chief Financial Officer, Vice President, Finance and Administration | $268.17K | $117.47K | $140.44K | – | $320.23K | $846.31K | -23% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Apr 23, 2021
- Offer price
- $17.00
- Securities offered
- 6,000,000
- Gross proceeds
- $102.00M
- Exchange
- Nasdaq
- First trading day
- Apr 22, 2021
- First-day close
- $24.96+46.8%
- Lock-up ends (est.)
- Oct 19, 2021
“The initial public offering price is $17.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 209 employees, all of which are based in the United States.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Apr 23, 2021 | IPO | Initial public offering priced (424B4 prospectus) |
| Apr 14, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?